RJFSA
BIO icon

Raymond James Financial Services Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-848
Closed -$304K – 3314
2023
Q3 		$304K Sell
848
-40
-5% -$15.4K ﹤0.01% 2641
2023
Q2 		$337K Sell
888
-1,341
-60% -$546K ﹤0.01% 2586
2023
Q1 		$1.07M Buy
2,229
+1,382
+163% +$647K ﹤0.01% 1864
2022
Q4 		$356K Sell
847
-128
-13% -$51.7K ﹤0.01% 2475
2022
Q3 		$407K Buy
975
+46
+5% +$22.9K ﹤0.01% 2368
2022
Q2 		$460K Buy
929
+3
+0.3% +$1.56K ﹤0.01% 2335
2022
Q1 		$522K Sell
926
-1,503
-62% -$906K ﹤0.01% 2353
2021
Q4 		$1.83M Buy
2,429
+1,074
+79% +$804K ﹤0.01% 1600
2021
Q3 		$1.01M Buy
1,355
+81
+6% +$60.7K ﹤0.01% 1949
2021
Q2 		$821K Buy
1,274
+115
+10% +$70K ﹤0.01% 2075
2021
Q1 		$662K Sell
1,159
-993
-46% -$588K ﹤0.01% 2106
2020
Q4 		$1.25M Sell
2,152
-372
-15% -$212K ﹤0.01% 1565
2020
Q3 		$1.3M Buy
2,524
+1,736
+220% +$879K ﹤0.01% 1385
2020
Q2 		$356K Buy
788
+74
+10% +$32.7K ﹤0.01% 2137
2020
Q1 		$250K Sell
714
-854
-54% -$314K ﹤0.01% 1947
2019
Q4 		$580K Sell
1,568
-168
-10% -$59.2K ﹤0.01% 1871
2019
Q3 		$578K Buy
1,736
+344
+25% +$112K ﹤0.01% 1812
2019
Q2 		$435K Buy
1,392
+11
+0.8% +$3.29K ﹤0.01% 2011
2019
Q1 		$422K Sell
1,381
-1,392
-50% -$376K ﹤0.01% 1997
2018
Q4 		$644K Sell
2,773
-161
-5% -$43.2K ﹤0.01% 1512
2018
Q3 		$918K Buy
2,934
+75
+3% +$23.3K ﹤0.01% 1517
2018
Q2 		$825K Sell
2,859
-9
-0.3% -$2.48K ﹤0.01% 1541
2018
Q1 		$717K Sell
2,868
-3,349
-54% -$853K ﹤0.01% 1515
2017
Q4 		$1.48M Buy
6,217
+188
+3% +$45.6K 0.01% 1049
2017
Q3 		$1.34M Sell
6,029
-335
-5% -$75.4K 0.01% 1122
2017
Q2 		$1.44M Buy
6,364
+78
+1% +$17K 0.01% 1039
2017
Q1 		$1.25M Buy
+6,286
New +$1.21M 0.01% 1052

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raymond James Financial Services Advisors's BIO Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 848 shares — an estimated $304K sold.

Raymond James Financial Services Advisors first reported a position in BIO in Q1 2017 and held it in 27 quarters. The position peaked at $1.83M in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 848 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $304K.
  • Raymond James Financial Services Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 27 quarters.
  • Raymond James Financial Services Advisors's Bio-Rad Laboratories Class A position peaked at $1.83M in Q4 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.